A phase I, multicenter, open-label safety, pharmacokinetic and preliminary efficacy study of wild-type sparing egfr inhibitor, ac0010ma, in adult patients with previously treated egfrmut and acquired T790M mutation non-small cell lung cancer (NSCLC)
2017-002743-16Cáncer de pulmón de células no pequeñasFundación Jiménez DíazInvestigador: Moreno García Víctor
